News | October 13, 2008

GE Launches New PET/CT at European Nuclear Medicine Meeting

October 14, 2008 - GE Healthcare introduced Discovery PET/CT 600, its newest positron emission tomography/computed tomography (PET/CT) system at the annual meeting of the European Association of Nuclear Medicine (EANM) Congress in Munich.

Recently cleared by the FDA, Discovery PET/CT 600 is part of GE’s Discovery family of scanners designed to enable earlier detection and accurate monitoring of disease with molecular imaging technology in both hardware and software.

Discovery PET/CT 600 is optimized for use in oncology, which represents more than 90 percent of clinical PET/CT exams. The system leverages the high-speed, high-resolution capabilities of GE’s BrightSpeed CT with the breakthrough motion management capabilities of its Discovery PET system. By combining these scanning technologies, the Discovery PET/CT 600 provides the tools to enable physicians to manage disease with more confidence.

As a key component of the image chain, the Discovery PET/CT 600 includes a scintillator with a proven track record and the highest sensitivity in the industry. GE BGO technology allows for improved lesion detectability, potentially reducing the dose requirement and allowing for faster scans and increased throughput.

For clinicians, the Discovery PET/CT 600 will provide a large 70cm bore that offers a full 70cm PET and CT Field-of-View and a ~225kg (500 lbs.) patient table. The GE Discovery PET/CT 600 offers an increased vertical scan range that provides more flexibility in radiation treatment planning and patient positioning.

“The Discovery PET/CT 600 platform was built for physicians and molecular imaging researchers based on their clinical need for more quantitative accuracy and the power to explore the potential of PET/CT imaging,” said Henry Hummel, general manager of GE Healthcare’s global PET/CT business.

For more information: www.gehealthcare.com

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init